Nomacopan

Summary

Nomacopan (CHEMBL4297928) is a phase-3 clinical-stage unknown; indicated across 2 conditions including bullous pemphigoid and hemoglobinuria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297928
Name	Nomacopan
Type	Unknown
Max phase	3

Also known as: Coversin, Nomacopan, REV-576, REV-675, REV675, rEV576, NOMACOPAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bullous pemphigoid	3	MONDO:0019082	EFO:0007187
hemoglobinuria	3	MONDO:0003656	MONDO:0100244

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04784455	PHASE3	TERMINATED	Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
NCT05061771	PHASE3	WITHDRAWN	Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
NCT02591862	PHASE2	COMPLETED	Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)
NCT03427060	PHASE2	COMPLETED	Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).